Russia will release its vaccine from nasal administration anticovid Sputnik in the first quarter of 2022, as reported on Wednesday, December 29, 2021 by the Centro Gamelaya, producer of this drug.
“The Sputnik nasal vaccine will be supplied to the market in the first quarter of 2022,” the center reported on its official Twitter account.
According to the Gamaleya Center, nasal vaccine, on whose development Russia reported mid-year, “it will be especially effective against the highly contagious Omicron variant, since it will not only protect against infection, but it will prevent transmission ”.
Gamaleya Center: “Sputnik nasal vaccine will be especially effective against highly transmissible #Omicron variant not only in terms of protection from infection but alsо at preventing transmission. Sputnik nasal vaccine will be supplied to market already in 1st quarter 2022” pic.twitter.com/P8uiVNxKDB
– Sputnik V (@sputnikvaccine) December 29, 2021
The President of Russia, Vladimir Putin, who participated last November in the trials of the nasal preparation, highlighted yesterday that the Russian two-dose anticovid vaccine Sputnik V it is highly effective against the Omicron variant and stated that it “guarantees about 90% protection.”
So far, Sputnik V has been approved for use in more than 70 countries and 21 other states have given Sputnik Light their go-ahead as well.
The creators of the russian vaccine argue that at the moment there is no need to develop a new drug for the Omicron variant.
–
